Company Product Description Indication Status
Carsgen Therapeutics Co. Ltd., of Shanghai AB-011 Monoclonal antibody targeting claudin18.2 Advanced gastric and pancreatic adenocarcinoma National Medical Products Administration in China cleared IND
Dermira Inc., of Menlo Park, Calif. Lebrikizumab Monoclonal antibody targeting IL-13 Moderate to severe atopic dermatitis FDA granted fast track designation
Dyve Biosciences Inc., of Thousand Oaks, Calif. DYV-700 Undisclosed drug using a delivery system Acute gout flare FDA cleared the start of a phase II study
Equillium Inc., of La Jolla, Calif. Itolizumab  Monoclonal antibody targeting CD6 Lupus nephritis FDA granted fast track designation
Inmed Pharmaceuticals Inc., of Vancouver, British Columbia INM-755 Cannabinoid-based topical cream Healthy volunteers (eventually epidermolysis bullosa) Received regulatory and ethics board approval for a clinical trial application for a phase I study
Navigen Inc., of Salt Lake City CPT-31 D-Peptide HIV entry inhibitor Healthy volunteers (eventually HIV infection) FDA cleared IND
Newron Pharmaceuticals SpA, of Milan Sarizotan Targets serotonin or dopamine receptors Rett syndrome Company plans to request a type A meeting with the FDA prior to unblinding of the Stars clinical trial data
Vertex Pharmaceuticals Ltd., of London Kalydeco (ivacaftor) CFTR potentiator Cystic fibrosis European Commission granted approval of the label extension for patients ages 6 months to 12 months with 9 specific CFTR mutations
Vistagen Therapeutics Inc., of South San Francisco PH-94B Activates nasal chemosensory receptors Social anxiety disorder FDA granted fast track designation

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments